1. Home
  2. MLYS vs NPKI Comparison

MLYS vs NPKI Comparison

Compare MLYS & NPKI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • NPKI
  • Stock Information
  • Founded
  • MLYS 2019
  • NPKI 1932
  • Country
  • MLYS United States
  • NPKI United States
  • Employees
  • MLYS N/A
  • NPKI N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • NPKI Metal Fabrications
  • Sector
  • MLYS Health Care
  • NPKI Industrials
  • Exchange
  • MLYS Nasdaq
  • NPKI Nasdaq
  • Market Cap
  • MLYS 526.1M
  • NPKI 621.1M
  • IPO Year
  • MLYS 2023
  • NPKI N/A
  • Fundamental
  • Price
  • MLYS $10.86
  • NPKI $7.01
  • Analyst Decision
  • MLYS Strong Buy
  • NPKI
  • Analyst Count
  • MLYS 2
  • NPKI 0
  • Target Price
  • MLYS $30.00
  • NPKI N/A
  • AVG Volume (30 Days)
  • MLYS 263.5K
  • NPKI 385.2K
  • Earning Date
  • MLYS 03-20-2025
  • NPKI 02-19-2025
  • Dividend Yield
  • MLYS N/A
  • NPKI N/A
  • EPS Growth
  • MLYS N/A
  • NPKI N/A
  • EPS
  • MLYS N/A
  • NPKI N/A
  • Revenue
  • MLYS N/A
  • NPKI $748,372,000.00
  • Revenue This Year
  • MLYS N/A
  • NPKI N/A
  • Revenue Next Year
  • MLYS N/A
  • NPKI N/A
  • P/E Ratio
  • MLYS N/A
  • NPKI N/A
  • Revenue Growth
  • MLYS N/A
  • NPKI 93.70
  • 52 Week Low
  • MLYS $8.58
  • NPKI $5.61
  • 52 Week High
  • MLYS $16.91
  • NPKI $8.65
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 51.57
  • NPKI N/A
  • Support Level
  • MLYS $9.81
  • NPKI N/A
  • Resistance Level
  • MLYS $10.79
  • NPKI N/A
  • Average True Range (ATR)
  • MLYS 0.62
  • NPKI 0.00
  • MACD
  • MLYS 0.15
  • NPKI 0.00
  • Stochastic Oscillator
  • MLYS 100.00
  • NPKI 0.00

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

About NPKI NPK International Inc. Common Stock

NPK International Inc Formerly Newpark Resources Inc is a diversified supplier providing environmentally-sensitive products, as well as rentals and services to customers across multiple industries. The company has two operating segments: Industrial Solutions and Fluids Systems. Fluids Systems segment which generates the majority of the revenue, provides drilling, completion, and stimulation fluids products and related technical services to customers for oil, natural gas, and geothermal projects. Geographically, the company derives majority of its revenue from the United States and also has its presence in Canada, EMEA, Latin America, and Asia Pacific regions.

Share on Social Networks: